Search Results

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical”), announces that it, along with certain others, filed a Notice of Civil Claim (the “Claim”) in the British Columbia Supreme Court on June 5, 2024 against its former legal counsel (the “Defendants”).

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that it has signed a License Data and Technical Information Agreement with Columbia University for rights to data from a randomized, active-controlled trial of 80 patients hospitalized for Acute Suicidality in Depression.

Earlier this year, scientists from Columbia University in New York demonstrated that the growth rate of pancreatic cancer, measured in patients’ blood using CA19-9 as biomarker, determines survival chances and can be used as a quick way to assess treatment effectiveness.

Thylacine Biotherapeutics Inc. (“Thylacine Bio”), a privately held biotech company dedicated to combating infectious disease, announced today it has entered into a license agreement with Columbia University (“Columbia”) for worldwide exclusive rights to develop and commercialize a novel antiviral peptide platform.

Altasciences is pleased to announce the completion of its laboratory facilities in Columbia, MO.